These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1129 related articles for article (PubMed ID: 24657486)

  • 1. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
    Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
    Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feedback regulation of methyl methanesulfonate and ultraviolet-sensitive gene clone 81 via ATM/Chk2 pathway contributes to the resistance of MCF-7 breast cancer cells to cisplatin.
    Lv J; Qian Y; Ni X; Xu X; Dong X
    Tumour Biol; 2017 Mar; 39(3):1010428317694307. PubMed ID: 28347251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
    J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Claudin-4: a potential therapeutic target in chemotherapy-resistant ovarian cancer.
    Yoshida H; Sumi T; Zhi X; Yasui T; Honda K; Ishiko O
    Anticancer Res; 2011 Apr; 31(4):1271-7. PubMed ID: 21508375
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of active mitogen-activated protein kinase in ovarian serous carcinomas.
    Hsu CY; Bristow R; Cha MS; Wang BG; Ho CL; Kurman RJ; Wang TL; Shih IeM
    Clin Cancer Res; 2004 Oct; 10(19):6432-6. PubMed ID: 15475429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
    Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
    Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Studying platinum sensitivity and resistance in high-grade serous ovarian cancer: Different models for different questions.
    Alkema NG; Wisman GB; van der Zee AG; van Vugt MA; de Jong S
    Drug Resist Updat; 2016 Jan; 24():55-69. PubMed ID: 26830315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients.
    Mignogna C; Staropoli N; Botta C; De Marco C; Rizzuto A; Morelli M; Di Cello A; Franco R; Camastra C; Presta I; Malara N; Salvino A; Tassone P; Tagliaferri P; Barni T; Donato G; Di Vito A
    J Ovarian Res; 2016 May; 9(1):31. PubMed ID: 27209210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ERCC1 expression as a predictor of resistance to platinum-based chemotherapy in primary ovarian cancer.
    Muallem MZ; Braicu I; Nassir M; Richter R; Sehouli J; Arsenic R
    Anticancer Res; 2014 Jan; 34(1):393-9. PubMed ID: 24403493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible degradation of checkpoint kinase 2 links to cisplatin-induced resistance in ovarian cancer cells.
    Zhang P; Gao W; Li H; Reed E; Chen F
    Biochem Biophys Res Commun; 2005 Mar; 328(2):567-72. PubMed ID: 15694385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initiation of the ATM-Chk2 DNA damage response through the base excision repair pathway.
    Chou WC; Hu LY; Hsiung CN; Shen CY
    Carcinogenesis; 2015 Aug; 36(8):832-40. PubMed ID: 26025911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of copper transporter expression with platinum resistance in epithelial ovarian cancer.
    Yoshida H; Teramae M; Yamauchi M; Fukuda T; Yasui T; Sumi T; Honda K; Ishiko O
    Anticancer Res; 2013 Apr; 33(4):1409-14. PubMed ID: 23564780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurora-A controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks.
    Sun H; Wang Y; Wang Z; Meng J; Qi Z; Yang G
    Biochim Biophys Acta; 2014 May; 1843(5):934-44. PubMed ID: 24480460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin.
    Soyama H; Miyamoto M; Takano M; Aoyama T; Matsuura H; Sakamoto T; Takasaki K; Kuwahara M; Kato K; Yoshikawa T; Iwahashi H; Tsuda H; Furuya K
    Med Oncol; 2017 Nov; 34(12):201. PubMed ID: 29168038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
    Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
    Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.
    Tomar T; Alkema NG; Schreuder L; Meersma GJ; de Meyer T; van Criekinge W; Klip HG; Fiegl H; van Nieuwenhuysen E; Vergote I; Widschwendter M; Schuuring E; van der Zee AGJ; de Jong S; Wisman GBA
    BMC Med; 2017 Jun; 15(1):116. PubMed ID: 28641578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
    van Jaarsveld MT; Helleman J; Boersma AW; van Kuijk PF; van Ijcken WF; Despierre E; Vergote I; Mathijssen RH; Berns EM; Verweij J; Pothof J; Wiemer EA
    Oncogene; 2013 Sep; 32(36):4284-93. PubMed ID: 23045278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 57.